Related Experiment Video
Updated: Dec 1, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer
Hans Tesch1, Volkmar Müller2, Achim Wöckel3
1Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany.
Abstract:
Substances with good effectiveness that intervene in specific signalling pathways have been used increasingly in recent years in the treatment of patients with advanced breast cancer, and new therapies and approaches have now been added, which actually relate to quite specific changes, such as the treatment of patients with HR+/HER2 tumours with a PIK3CA mutation. The treatment of patients with a BRCA1 or BRCA2 mutation has also been improved by the introduction of PARP inhibitors. Attempts are now being made increasingly to extend treatment indications based on molecular patterns, to identify other patients who could benefit from a treatment and to integrate the newly established treatment methods in existing therapy sequences. This review articles summarises the latest information in this connection.
Insights
Targeted therapies are improving advanced breast cancer treatment by focusing on specific genetic mutations like PIK3CA and BRCA1/2. This review covers new approaches and integrating them into current treatment sequences for better patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Targeted therapies show increasing effectiveness in advanced breast cancer treatment.
- Recent advancements focus on specific molecular alterations for personalized treatment strategies.
Purpose of the Study:
- To review the latest information on targeted therapies for advanced breast cancer.
- To discuss the integration of new treatment methods based on molecular patterns.
Main Methods:
- Literature review of recent studies on targeted therapies in breast cancer.
- Analysis of treatment strategies for specific mutations (PIK3CA, BRCA1/2).
Main Results:
- PARP inhibitors have improved outcomes for patients with BRCA1/2 mutations.
- Targeted therapies for PIK3CA mutations are emerging for HR+/HER2 advanced breast cancer.
Conclusions:
- Personalized medicine based on molecular profiling is expanding treatment options.
- Integrating novel therapies into existing sequences is crucial for optimizing patient care.
More Related Videos
05:05Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy
Published on: November 29, 2018
03:07Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
Related Concept Videos
Cancer Survival Analysis
Treatment Resistant Cancers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Prevention
Some...